Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: placebo + through + 19,500  Related to the article below (Last Update: 8/5/2008)

Reiki had initial problems gaining acceptance, but users find a ...
Irish Times, Ireland -
Criticised in some quarters for being nothing more than an example of the placebo effect in action and in others as a pseudo-religion which invites evil ...
Tracleer(R) (bosentan) receives EU approval for treatment of ...
FOXBusiness -
The PAH progression was evident from the deterioration in all evaluated parameters in the placebo group, including the rate of clinical worsening events. ...VTX:ATLN - OTC:CMTX
VIVUS Reports Second Quarter 2008 Financial Results and Highlights
Business Wire (press release), CA -
Subjects treated with Qnexa also lost 8.0% of their baseline body weight, or 7.7 kg, as compared to 1.2% weight loss, or 1.3 kg, observed in the placebo ...VVUS - KV.A
Pharmasset Reports Preliminary Results of a 4-week Combination ...
CNNMoney.com (press release) - 31 minutes ago
Of the 31 patients enrolled, 25 patients received R7128 1000mg BID and 6 received placebo. 88% (22 of 25) patients receiving R7128 1000mg BID with SOC for 4 ...VRUS
Creatine a Bust for Boosting Exercise Benefit in COPD
MedPage Today, NJ -
... creatine -- 22 grams a day for five days as a loading dose, then 3.76 grams a day through the rest of the program -- and other half received placebo. ...

MedPage Today
/CORRECTION -- Medivation, Inc./
MarketWatch - Jul 30, 2008
New data from a six-month open-label extension of the 12-month placebo-controlled study of Dimebon in patients with mild-to-moderate Alzheimer's disease ...
Baxter Drug Shows Benefit Vs Alzheimer's After 9 Months - Study CNNMoney.com
ICAD: Investigational Alzheimer's Drug Found Beneficial in ... MedPage Today
Baxter's Immune Boosting Drug May Help Alzheimer's (Update2) Bloomberg
guardian.co.uk - MarketWatch
all 85 news articles »  BAX - MDVN - OTC:CMTX
Toxic Drugs, Toxic System: Sociologist Predicts Drug Disasters
Science Daily (press release) -
Approvals are based on these data; so drugs with harmful effects sometimes get through. "Based on our current system, the designation of 'safe and ...

Business Wire (press release)
Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial ...
Business Wire (press release), CA - 32 minutes ago
In a model of CIA, mice were immunized to induce disease and were then treated orally with TRIOLEX or placebo beginning one week after disease onset. ...HEPH
AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical ...
MarketWatch - Jul 31, 2008
The placebo group decreased 0.2% from baseline. In the trial, a regional variation was observed in the placebo arm. Eastern Europe showed a significant ...
QualityStocks News ? AtheroGenics Inc. (AGIX) Reports Positive ... TransWorldNews (press release)
all 18 news articles »  AGIX
BELLUS Health moves forward on nutraceutical and pharmaceutical ...
Canada NewsWire (press release), Canada - 31 minutes ago
"The matching individuals taking VIVIMIND(TM) also performed better on tests of memory and thinking compared with individuals taking a placebo. ...BLUS
Source: Google News

[PDF] Antiviral activity, pharmacokinetics, safety and tolerability of R-7128, a novel nucleoside HCV RNA …
R Reddy, M Rodriguez-Torres, E Gane, R Robson, J … - Hepatology, 2007 - files.shareholder.com
... R7128 demonstrated dose-dependent HCV RNA decreases through 14 days ... N=8 750mg QD
N=8 Placebo QD/BID N ... 19600) 7381.3 (5390-9450) 11538.7 (6580-19500) 7217.5 (4420 ...

The effects of creatine pyruvate and creatine citrate on performance during high intensity exercise -
R J?ger, J Metzger, K Lautmann, V Shushakov, M … - Journal of the International Society of Sports Nutrition, 2008 - pubmedcentral.nih.gov
... Study Protocol. A double-blind, placebo-controlled study ... maximum 3 cm- was recorded
through an inductive ... hematocrit (Hct, microcentrifugation at 19500 g, Biofuge ...
-

Rheological evaluation and ocular contact time of some carbomer gels for ophthalmic use -
K Edsman, J Carlfors, K Harju - International Journal of Pharmaceutics, 1996 - Elsevier
... important for increasing the amount of drug entering through the cornea. ... in which
the left eye was given a placebo solution ... 0.01 1.5 2680 3300 11900 2550 19500 ...

The Endocannabinoid System as a Target for the Treatment of Visceral Obesity and Metabolic Syndrome -
I KYROU, G VALSAMAKIS, C TSIGOS - Annals of the New York Academy of Sciences, 2006 - Blackwell Synergy
... The newly discovered endocannabinoid system, through the reported role ... prospective,
randomized, international, multicenter double blind placebo control trials ...

[PDF] The molecular logic of endocannabinoid signalling -
D Piomelli - Nature Reviews Neuroscience, 2003 - fbmc.fcen.uba.ar
... Cannabis). They are made on demand through cleavage of membrane precursors
and are involved in various short-range signalling processes. ...
-

Immune control by endocannabinoids?New mechanisms of neuroprotection? -
O Ullrich, K Merker, J Timm, S Tauber - Journal of Neuroimmunology, 2007 - Elsevier
... However, in a randomized, placebo-controlled, 21-day intervention trial, smoked
or ... The activity of NAT activity regulated by phosphorylation through PKA, but ...

Blood schizontocidal activity of azithromycin and its combination with [alpha]/[beta] arteether … -
R TRIPATHI, S DHAWAN, GP DUTTA - Parasitology, 2005 - pt.wkhealth.com
... million malaria cases and 19500 malaria-related ... mefloquine /quinine treatments through
successive passages ... double-blinded, randomized, placebo-controlled field ...

[PDF] Update on Pharmacoeconomics in Transplantation -
T Cavanaugh, JE Martin - Transplantation - aacn.org
... the hospital?s perspective, and the cost data were obtained through an activity ...
7-country, 21-center clinical trial that compared basiliximab with a placebo. ...

Cell?cellcommunication byEndocannabinoids during Immune SurveillanceoftheCentralNervousSystem
RPC Differ, E Gundelfinger, C Seidenbecher, B … - Springer
... endocannabi- noids mediate a localized signalling mechanism through which principal ...
Marinol?), capsules of cannabis extract Cannador? or placebo capsules, a ...
-

In Vivo Fatty Acid Incorporation into Brain Phospholipids in Relation to Signal Transduction and … -
SI Rapoport - Neurochemical Research, 1999 - Springer
... a "dilution factor" X, which esti- mates the contribution to the brain precursor
acyl-CoA pool of fatty acids released from phos- pholipids through the action ...

Source: Google Scholar

The Placebo Effect Explained Through Identification Of Relevent Brain Region
Researchers have pinpointed a brain region central to the machinery of the placebo effect -- the often controversial phenomenon in which a person's belief in the efficacy of a treatment such as a painkilling drug influences its effect.

The researchers said their findings with human subjects offer the potential of measuring the placebo effect and even modulating it for therapeutic purposes. They also said their findings could enable measurements of brain function that "would help determine dysfunctions in cerebral mechanisms that may impair recovery across a number of conditions."

Jon-Kar Zubieta and colleagues published their findings in the journal Neuron, published by Cell Press.
Their studies concentrated on a brain area known as the nucleus accumbens (NAC), a region deep in the brain, known to play a role in expectation of reward. Earlier studies had hinted at involvement of the NAC in the placebo effect, but the nature of that role was unknown, said the researchers.

In their experiments, the researchers told volunteers that they were testing the effects of a new pain-killing drug and that the subjects might receive the drug or a placebo. However, in the experiments, the researchers gave only a placebo injection of a salt solution. The experiments involved asking the subjects to rate their expectation of the pain-killing effects of the "drug" and also the level of pain relief with or without the "drug" that they felt from a moderately painful injection of salt solution into their jaw muscle.

In one set of experiments, the researchers used a molecular tracer scanning technique known as Positron Emission Spectroscopy to measure release from the NAC of the neurotransmitter dopamine - a chemical trigger of the brain's reward response. They found that the greater subjects' anticipation of the pain-killing benefit of the placebo, the greater the dopamine release from the NAC. Also, subjects who reported greater relief from the placebo when they did experience pain showed greater NAC activity when they received the placebo before the pain.

In separate experiments, the researchers studied whether activation of subjects' NAC during reward processing correlated with the magnitude of their placebo effect. They told subjects to expect monetary rewards of different amounts, as their brains were scanned using functional magnetic resonance imaging. The researchers found that the people who showed greater activation of the NAC during this reward-expectation task also showed a greater anticipation of effectiveness of a placebo.

The researchers concluded that "These findings are consistent with the hypothesis that this system is involved in the encoding of the 'incentive value' of the placebo, possibly acting as a gate or permissive system for the formation of placebo effects."

They wrote that "The placebo effect then emerges as a resiliency mechanism with broad implications that, given its activation of specific circuits and mechanisms, can be both examined and modulated for therapeutic purposes."

The researchers include David J. Scott, Christine M. Egnatuk, Heng Wang, Robert A., Koeppe, and Jon-Kar Zubieta of The University of Michigan, Ann Arbor; Christian S. Stohler of University of Maryland, Baltimore. This work was supported by grants R01 AT 001415 and R01 DA 016423 to J.K.Z. and R01 DE 15396 to C.S.S.

Scott et al.: "Individual Differences in Reward Responding Explain Placebo-Induced Expectations and Effects." Publishing in Neuron 55, 325-336, July 19, 2007. DOI 10.1016/j.neuron.2007.06.028. http://www.neuron.org/.

Source: Erin Doonan
Cell Press
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.